| First Author | Xie J | Year | 2024 |
| Journal | iScience | Volume | 27 |
| Issue | 4 | Pages | 109612 |
| PubMed ID | 38632995 | Mgi Jnum | J:347639 |
| Mgi Id | MGI:7625103 | Doi | 10.1016/j.isci.2024.109612 |
| Citation | Xie J, et al. (2024) Extracellular vesicles-derived CXCL4 is a candidate serum tumor biomarker for colorectal cancer. iScience 27(4):109612 |
| abstractText | Extracellular vesicles (EVs) were promising circulating biomarkers for multiple diseases, but whether serum EVs-derived proteins could be used as a reliable tumor biomarker for colorectal cancer (CRC) remained inconclusive. In this study, we identified CXCL4 by a 4D data-independent acquisition-based quantitative proteomics assay of serum EVs-derived proteins in 40 individuals and subsequently analyzed serum EVs-derived CXCL4 levels by ELISA in 2 cohorts of 749 individuals. The results revealed that EVs-derived CXCL4 levels were dramatically elevated in CRC patients than in benign colorectal polyp patients or healthy controls (HC). Furthermore, receiver operating characteristic curves revealed that EVs-derived CXCL4 exhibited superior diagnostic performance with area under the curve of 0.948 in the training cohort. Additionally, CXCL4 could effectively distinguish CRC in stage I/II from HC. Notably, CRC patients with high levels of EVs-derived CXCL4 have shorter 2-year progression-free survival than those with low levels. Overall, our findings demonstrated that serum EVs-derived CXCL4 was a candidate diagnostic and prognostic biomarker for CRC. |
